The T877S and H874Y mutations in ARs are induced by treatment with androgen receptor (AR) antagonists such as hydroxyflutamide, and a single mutation in the AR transactivates the AR-signaling pathway in the prostate cancer [82]. The gene discussed is AR; the disease is Familial prostate cancer.